Pharmafile Logo

News and Press Releases

SciRhom Initiates Dosing in First-in-Man Clinical Study Evaluating the Company’s Lead Development Program SR-878

Transition into clinical-stage development marks a significant corporate and R&D milestone 17 October 2024 -- Munich, Germany -- SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 17, 2024

SciRhom
info@SciRhom.com
Am Klopferspitz 19 82152 Planegg/Martinsried Germany

SciRhom Secures €63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases

The upsized and oversubscribed Series A financing round will be used to drive the lead development programme toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2...

Category: Drug Discovery, Other, Pharmaceutical
Posted: July 9, 2024

SciRhom
info@SciRhom.com
Am Klopferspitz 19 82152 Planegg/Martinsried Germany

Epsilogen announces CTA approval for phase 1b trial of MOv18 IgE in platinum-resistant ovarian cancer

Phase 1b study expected to initiate in H2 2024 Previously reported phase 1 results showed MOv18 IgE to be safe and well-tolerated, with evidence of anti-tumour activity. 8 July 2024...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: July 8, 2024

Epsilogen
info@epsilogen.com
Waterfront, ARC West London, Manbre Road, Hammersmith, London, W6 9RH

SciRhom Announces Approval of First Clinical Trial Application for a Novel iRhom2-targeting Antibody Against Autoimmune Diseases

12 June 2024 -- Munich, Germany -- SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic antibodies, announced today the approval of a clinical trial application (CTA) by...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 12, 2024

SciRhom
info@SciRhom.com
Am Klopferspitz 19 82152 Planegg/Martinsried Germany

argenx Announces MHRA Licensing of Subcutaneous VYVGART (efgartigimod alfa) for generalised Myasthenia Gravis

VYVGART is now licensed for both intravenous (IV) and self-administered subcutaneous (SC) use in the UK 7 February 2024 -- Gerrards Cross, UK -- argenx UK, part of argenx, a...

Category: Biotechnology
Posted: February 7, 2024

argenx
ukmediainfo@argenx.com
Spaces Gerrards Cross Chalfont Park, Building 1 Gerrards Cross, SL9 0BG

Medicines and Healthcare Products Regulatory Agencyauthorises GSK’s Omjjara (momelotinib) in Great Britainfor treating splenomegaly or symptoms in adultmyelofibrosis patients with moderate to severe anaemia

First JAK inhibitor treatment in Great Britain specifically indicated for both newly diagnosed and previously treated myelofibrosis patients with moderate to severe anaemia 31 January 2024 -- Middlesex, UK --...

Category: Pharmaceutical
Posted: January 31, 2024

GSK
980 Great West Rd, London TW8 9GS

Calypso Enters into Agreement to Be Acquired by Novartis

Calypso is a European biotech translating Interleukin-15 biology into medical breakthroughs by developing CALY-002, an anti-IL-15 monoclonal antibody, for an array of autoimmune indications The acquisition of Calypso gives Novartis...

Category: Biotechnology
Posted: January 8, 2024

Calypso Biotech
Gustav Mahlerplein 102 1082 MA Amsterdam The Netherlands